Clinical Trial

A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Adult Study Participants With Non-Cystic Fibrosis Bronchiectasis

Study acronym: ATMOS
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of the study is to investigate the efficacy of galvokimig versus placebo on the time to the first pulmonary exacerbation in study participants with non-cystic fibrosis bronchiectasis (NCFB)
Protocol Amendment History 2 changes
critical Recruitment opened 2026-08-12
notable Trial sites expanded: 0 -> 3 locations 2026-08-12
Trial Details
NCT Number NCT07720375
Lead Sponsor UCB Biopharma SRL
Conditions Non-cystic Fibrosis Bronchiectasis
Enrollment 300 participants
Start Date 2026-08-05
Primary Completion 2029-02-28 (estimated)
Study Completion 2029-04-26 (estimated)
Updated on ClinicalTrials.gov 2026-08-11